Biotech Consultants

Innovative biotech products such as cell and gene therapies, CAR-T, monoclonal antibodies, and peptides are reshaping the future of healthcare. But success in China and Asia Pacific requires more than scientific innovation. However, successfully navigating China and Asia Pacific requires more than innovation. With evolving regulatory landscapes, diverse access pathways, and complex approval processes, companies need more than a local presence, they need a consulting partner with deep biotech expertise, regulatory foresight, and operational precision.

Cisema’s biotech consulting services support life sciences companies in navigating regulatory complexity, accelerating approvals, and optimizing commercialization across China and the Asia Pacific region. From early development through post-market compliance, we offer tailored solutions that drive success across at every stage of the biotech product lifecycle.

Biotech consultants
Biotech consultant
Biotech Consultants

Our services include:

Regulatory strategy and submission planning tailored for advanced therapies
Market access solutions aligned with real-world data and regional payer needs
End-to-end GxP quality and compliance support across the product lifecycle
Pharmacovigilance systems adapted to local requirements and global best practices

Whether you are developing novel therapies, initiating clinical trials, or expanding into Asia Pacific, our biotech consultants deliver solutions built for success in today’s complex regulatory landscape.

Discover Our Biotech Consulting Services

Biotech Product Development & Strategy

We help bring breakthrough therapies to market with confidence. Our development and strategy services are designed to establish strong regulatory foundations, mitigate development risks, and accelerate timelines to market.

Scientific and regulatory due diligence to assess feasibility and compliance
Gap analysis for cell and gene therapies, monoclonal antibodies, and peptides
Clinical development planning and regulatory strategy
Engagement with regulatory authorities
Scientific and technical writing for high-quality regulatory submissions

Health Economics & Market Access

We accelerate patient access and unlock commercial potential for innovative therapies. Our market access consultants help biotech companies navigate pricing and reimbursement frameworks, deliver strong value narratives, and align with health policy priorities across Asia Pacific.

Regulatory market intelligence
Payer engagement planning and stakeholder mapping
Health economics modeling and value dossier development
Pricing and reimbursement support
Competitive landscape analysis and HTA readiness

Regulatory Affairs for Biotech

Advance your biotech innovations with clarity and confidence. Cisema supports life sciences companies in navigating complex regulatory pathways for advanced therapies, from IND applications to marketing authorizations and post-market maintenance.

Strategic regulatory roadmaps and lifecycle planning
Regulatory authority engagement and meeting support
CTD dossier authoring, compilation, and submission
Country-specific adaptation and localization of global dossiers
Legal agent and representation services to ensure full compliance

Biotech Quality Management & Compliance

We ensure operational excellence and regulatory alignment. Our quality and compliance experts help biotech companies build and maintain robust quality systems, meet GxP standards, and prepare for inspections across China and Asia Pacific.

GxP audits and QMS/SOP reviews
Ingredient compliance and vendor audits
Pre-approval inspection readiness and support
Remediation planning and CAPA implementation

Pharmacovigilance for Biotech

We help safeguard patient safety while ensuring full regulatory compliance with confidence. Our pharmacovigilance services enable biotech companies to manage risk, maintain product safety, and meet stringent reporting obligations throughout clinical development and post-market phases.

Signal detection and safety risk management
Case processing and regulatory submissions
Clinical trial safety monitoring
PV audits and system readiness
Local QPPV services and post-market surveillance

Why Cisema?

Cisema brings together deep scientific expertise, regional regulatory insight, and over two decades of experience supporting novel therapies. Our biotech consultants are trusted by global innovators for their expertise in navigating Asia Pacific’s complex regulatory landscape.

We will help you:

build and execute region-specific strategies for advanced therapies
optimize development and submission timelines
align with HTA, payer, and policy expectations
ensure inspection readiness and regulatory compliance
expand market access and commercial reach

Whether you are advancing a gene therapy or commercializing a peptide, we support biotech success from discovery to delivery.

Pharma and healthcare expertise from the Cisema team

Other Industries We Support

In addition to pharmaceuticals and biotech, we offer consulting services across regulated industries, including medical devices, IVDs, cosmetics, health foods, veterinary products, and other industrial and consumer goods. Our team ensures tailored regulatory compliance strategies, regardless of product category or manufacturing model.

Medical Devices

In-Vitro Diagnostics

Cosmetics

Pharmaceuticals

Health Foods & Supplements

Veterinary Medicines & Products

Industrial Goods & Consumer Products

Latest Insights

View More

Hong Kong Launches Primary Evaluation Phase 1 for NDAs

Hong Kong introduces Primary Evaluation Phase 1 for NDAs, requiring pathway selection across 3 routes and reshaping drug registration strategy.

May 6, 2026
Hong Kong Launches Primary Evaluation Phase 1 for NDAs
A single Asian scientist in their 30s wearing a lab coat, safety glasses, and nitrile gloves seated at a tidy bench in a modern pharmaceutical laboratory in Hong Kong, calmly reviewing a few printed documents while referencing a simple laptop screen

Hong Kong Clarifies Injectable Products Are Regulated as Pharmaceutical Products Under Cap. 138

Hong Kong confirms injectable products are generally classified as pharmaceutical products under Cap. 138, impacting medical aesthetics and borderline products

May 8, 2026
Hong Kong Clarifies Injectable Products Are Regulated as Pharmaceutical Products Under Cap. 138
Minimalist, well-lit medical aesthetics clinic in Hong Kong. An Asian female doctor in a simple white coat and disposable gloves sits beside a female patient, holding a single unbranded prefilled syringe at chest level.

China April 2026 Reforms Reshape Drug Approval, Pricing, & Access

The reforms introduce new drug pricing rules, clarified conditional approval procedures, and tiered care measures.

May 8, 2026
China April 2026 Reforms Reshape Drug Approval, Pricing, & Access
Chinese scientists gathered around a bottle of medicine

China’s New AI Ethics Measures Increase Scrutiny of High-Impact AI, Including Health-Related Technologies

China’s MIIT and nine ministries introduce a new AI ethics review and services framework establishing tiered oversight, compliance obligations, and governance pathways for AI activities in China.

April 28, 2026
China’s New AI Ethics Measures Increase Scrutiny of High-Impact AI, Including Health-Related Technologies

BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation

BPOM confirms pharmaceutical authorization, GMP oversight, and regulatory authority remain unchanged under the Indonesia–US trade agreement.

April 23, 2026
BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation
Laboratory scientist wearing a lab coat, protective goggles, gloves, and a blue hair cover carefully examining a small vial of liquid in a modern laboratory. A tray of sample vials sits on the bench in front.

NMPA CDE Issues MRCT Benefit-Risk Assessment Guideline

China releases guiding principles for benefit-risk assessment using multi-regional clinical trial data to support global drug development.

April 23, 2026
NMPA CDE Issues MRCT Benefit-Risk Assessment Guideline
Previous
Previous

Get in Touch with Our Biotech Consultants

Speak to our biotech specialists to explore how our regulatory guidance, market access support, and operational expertise can help you bring innovative biotech therapies to market across China and Asia Pacific.

Request Proposal